Research graph
References from Public availability of trial-design and clinical-context information in contemporary lipoprotein(a)-targeted cardiovascular trials: A cross-sectional meta-research study. Local targets link to admitted publications; unresolved targets remain external evidence.
European atherosclerosis society consensus panel. Lipoprotein(a) as a cardiovascular risk factor: current status
10.1093/eurheartj/ehq386 · 2010 · External reference
A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies
10.1016/j.jacc.2016.11.042 · 2017 · External reference
Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association
10.1161/atv.0000000000000147 · 2022 · External reference
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement
10.1093/eurheartj/ehac361 · 2022 · External reference
A focused update to the 2019 National Lipid Association scientific statement on use of lipoprotein(a) in clinical practice
10.1016/j.jacl.2024.03.001 · 2024 · External reference
Lipoprotein(a) measurements for clinical application
10.1194/jlr.r061648 · 2016 · External reference
Lipoprotein(a) reduction in persons with cardiovascular disease
10.1056/nejmoa1905239 · 2020 · External reference
Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease
10.1056/nejmoa2211023 · 2022 · External reference
Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial
10.1001/jama.2023.21835 · 2023 · External reference
Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a): a randomized clinical trial
10.1001/jama.2024.4504 · 2024 · External reference
Zerlasiran-a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial
10.1001/jama.2024.21957 · 2024 · External reference
Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial
10.1001/jama.2023.16503 · 2023 · External reference
Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial
10.1001/jama.2024.24017 · 2025 · External reference
Clinical trial design for lipoprotein(a)-lowering therapies: JACC focus seminar 2/3
10.1016/j.jacc.2023.02.033 · 2023 · External reference
Study design and rationale for the Olpasiran trials of cardiovascular events and lipoproteiN(a) reduction-DOSE finding study
10.1016/j.ahj.2022.05.004 · 2022 · External reference
Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with cardiovascular disease and elevated lipoprotein(a)
10.1016/j.ahj.2025.03.019 · 2025 · External reference
Lp(a): a rapidly evolving therapeutic landscape
10.1007/s11883-024-01252-0 · 2024 · External reference
Current clinical trials for treating elevated lipoprotein(a)
10.1007/s12170-025-00759-8 · 2025 · External reference
How to avoid common problems when using ClinicalTrials.gov in research: 10 issues to consider
2018 · External reference
The ClinicalTrials.gov results database-update and key issues
10.1056/nejmsa1012065 · 2011 · External reference
The database for aggregate analysis of ClinicalTrials.gov (AACT) and subsequent regrouping by clinical specialty
10.1371/journal.pone.0033677 · 2012 · External reference
Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review
10.1080/17512433.2020.1787832 · 2020 · External reference
Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps
10.1136/bmjgh-2024-017177 · 2024 · External reference
The strengthening the reporting of observational studies in epidemiology statement: guidelines for reporting observational studies
10.1016/s0140-6736(07)61602-x · 2007 · External reference
The reporting of studies conducted using observational routinely collected health data statement
10.1371/journal.pmed.1001885 · 2015 · External reference
PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews
10.1186/s13643-020-01542-z · 2021 · External reference
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials
10.1136/bmj.c332 · 2010 · External reference
SPIRIT 2013 statement: defining standard protocol items for clinical trials
10.7326/0003-4819-158-3-201302050-00583 · 2013 · External reference
Guidelines for reporting outcomes in trial reports: the CONSORT-outcomes 2022 extension
10.1001/jama.2022.21022 · 2022 · External reference
Guidelines for reporting outcomes in trial protocols: the SPIRIT-outcomes 2022 extension
10.1001/jama.2022.21243 · 2022 · External reference
Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research joint research statement
10.1200/jco.2017.73.7916 · 2017 · External reference
